2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
复制标题
DOI：
10.1093/annonc/mdw270
复制
发表时间：
2016-09-01
影响因子：
50.5
通讯作者：
van der Wetering, M.
中科院分区：
文献类型：
--
作者：
Roila, F.;Molassiotis, A.;van der Wetering, M.
尽管在过去的30年里取得了相当大的进展，呕吐，尤其是恶心，仍然是癌症化疗的两个最令人痛苦的副作用。在20世纪90年代后期，一些专业组织发表了关于化疗和/或放疗患者最佳止吐预防的建议。欧洲肿瘤医学学会（ESMO）和多国癌症支持护理协会（MASCC）在2010年6月的《肿瘤学年鉴》上发表了2009年6月在佩鲁贾举行的第三次止吐药共识会议的结果。2015年6月在哥本哈根讨论了这些建议的更新，包括2009年1月1日至2015年6月30日发表的研究，并在本文中提出。指南过程的方法在2010年出版物[1]中有详细描述。要改变2010年的建议或使新的指南建议被接受，至少需要67%的专家小组成员达成共识。作为一般规则，专家组认为10%或更大的变化足以证明有理由改变建议。ESMO证据等级[I-V]和推荐等级[A-D]是根据美国传染病学会的ESMO分级改编版本给出的。MASCC的科学信心水平被分类为
Despite the considerable progress achieved in the last 30 years, vomiting and, especially, nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In the late 1990s, several professional organisations published recommendations on the optimal antiemetic prophylaxis in patients submitted to chemotherapy and/or radiotherapy. The European Society of Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC) published the results of the third Consensus Conference on antiemetics held in Perugia in June 2009 in Annals of Oncology in 2010 [1]. An update of these recommendations, including studies published from 1 January 2009 to 30 June 2015, was discussed in Copenhagen in June 2015 and is presented in this paper. The methodology for the guideline process is described in detail in the 2010 publication [1]. To change a 2010 recommendation or for a new guideline recommendation to be accepted, a consensus of at least 67% of the expert panellists was needed. As a general rule, the panel considered changes of 10% or greater to be sufficient to warrant the changing of a recommendation.ESMO levels of Evidence [I–V] and Grades of Recommendation [A–D] are given according to the ESMO-adapted version of the grading of the Infectious Diseases Society of America. The MASCC Levels of Scientific Confidence was classified as